139 Shares in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) Bought by Union Bancaire Privee UBP SA

Union Bancaire Privee UBP SA bought a new stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 139 shares of the pharmaceutical company’s stock, valued at approximately $56,000.

Several other institutional investors have also recently bought and sold shares of the business. Czech National Bank increased its position in Vertex Pharmaceuticals by 6.2% during the 4th quarter. Czech National Bank now owns 55,838 shares of the pharmaceutical company’s stock worth $22,486,000 after purchasing an additional 3,260 shares in the last quarter. Whalen Wealth Management Inc. acquired a new position in shares of Vertex Pharmaceuticals during the third quarter worth $662,000. Mizuho Securities USA LLC lifted its stake in shares of Vertex Pharmaceuticals by 289.0% in the 3rd quarter. Mizuho Securities USA LLC now owns 77,393 shares of the pharmaceutical company’s stock valued at $35,994,000 after acquiring an additional 57,497 shares during the last quarter. Nordea Investment Management AB boosted its holdings in shares of Vertex Pharmaceuticals by 19.4% during the 4th quarter. Nordea Investment Management AB now owns 342,429 shares of the pharmaceutical company’s stock valued at $137,783,000 after acquiring an additional 55,739 shares in the last quarter. Finally, Keynote Financial Services LLC bought a new stake in Vertex Pharmaceuticals during the 3rd quarter worth $498,000. Institutional investors and hedge funds own 90.96% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently commented on VRTX. Cantor Fitzgerald reissued an “overweight” rating and set a $480.00 price target on shares of Vertex Pharmaceuticals in a research note on Friday, January 24th. Needham & Company LLC reiterated a “hold” rating on shares of Vertex Pharmaceuticals in a research report on Friday, December 20th. Piper Sandler decreased their price target on shares of Vertex Pharmaceuticals from $535.00 to $533.00 and set an “overweight” rating for the company in a research report on Monday. BMO Capital Markets cut their price target on shares of Vertex Pharmaceuticals from $566.00 to $520.00 and set an “outperform” rating on the stock in a report on Friday, December 20th. Finally, Royal Bank of Canada increased their price objective on Vertex Pharmaceuticals from $437.00 to $451.00 and gave the company a “sector perform” rating in a report on Tuesday, November 5th. Two analysts have rated the stock with a sell rating, ten have assigned a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $494.76.

Vertex Pharmaceuticals Stock Performance

Shares of VRTX stock opened at $441.52 on Thursday. The company has a debt-to-equity ratio of 0.01, a current ratio of 2.47 and a quick ratio of 2.20. The firm has a 50-day moving average of $434.75 and a 200-day moving average of $463.64. Vertex Pharmaceuticals Incorporated has a one year low of $377.85 and a one year high of $519.88. The company has a market cap of $113.70 billion, a P/E ratio of -221.87, a P/E/G ratio of 2.20 and a beta of 0.40.

Vertex Pharmaceuticals (NASDAQ:VRTX) last posted its quarterly earnings data on Monday, November 4th. The pharmaceutical company reported $4.38 EPS for the quarter, beating the consensus estimate of $3.61 by $0.77. Vertex Pharmaceuticals had a negative net margin of 4.52% and a negative return on equity of 1.91%. The firm had revenue of $2.77 billion during the quarter, compared to analyst estimates of $2.69 billion. During the same quarter last year, the business posted $3.67 EPS. The company’s revenue for the quarter was up 11.6% on a year-over-year basis. Equities research analysts forecast that Vertex Pharmaceuticals Incorporated will post -1.9 EPS for the current fiscal year.

Vertex Pharmaceuticals Company Profile

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.